The company

Toxys is a Dutch biotech company that provides innovative in vitro toxicity screening solutions to rapidly identify hazardous and potential carcinogenic properties of novel compounds during the early phases of product and drug development. We aim to bring information to our customers that is essential to make informed decisions on which compounds to progress in the drug/compound development pipeline, thereby contributing to the development of better medicines and products and to reduce animal testing.


We work we an experienced and enthusiastic team of people. Passion, quality and responsiveness characterize us.

Read more


Find out more about who has worked with the assay and who our development partners are.

Read more


We are an ambitious and growing company, approach us if you think you can contribute to our journey.

Read more

Toxys in 90 seconds

This video gives you a quick insight into what Toxys could do for you.

Meet us at one of the events we visit

SOT annual meeting 2020

You are cordially invited to join the ToxTracker event and launch party during the SOT 2020 meeting in Anaheim. During this event we will launch new assays, software and the ToxTracker Academy. We will also update you on the latest developments around ToxTracker and its regulatory status. Various ToxTracker users will share their experiences with the assay and how they integrated ToxTracker in their genotoxicity testing strategy. After the presentations, there will the opportunity to talk to the Toxys team, the speakers and other participants. Presentations: Giel Hendriks - CEO - Toxys Yax Thakkar - Genetic Toxicology Scientist - RIFM Ruth Danzeisen - Toxicologist - The Cobalt Institute Raja Settivari - Toxicologist - Corteva Agriscience When: March 16 between 5.00pm and 7.00pm Where: Hilton Anaheim, room California Ballroom A Register: If you want to join, please register via Snack and drinks will be provided You can also meet us at our posters: # 2134/P484 - The ToxTracker reporter assay as a tool for mechanism-based (geno)toxicity screening of nanoparticles – metals, oxides and quantum dots. # 1611/P732 - Validation of a Human Stem Cell-Based Biomarker Assay for In Vitro Developmental Toxicity Assessment # 2726/P327 - Development of an intracellular microtubule stability assay using GFP-tagged alpha-tubulin Or read more about ToxTracker on posters by others: # 1522/P624 - Next-generation risk assessment (NGRA) for cosmetic safety assessment: A Case Study (by Unilever) # 2689/P289 - Weight of evidence assessment of the genotoxicity of an extract of chinese skullcap - a traditional Chinese herbal medicine (by New Chapter/Proctor & Gamble) # 2701/P301 - Determination of the Genotoxic potential of E-cigarette aerosols and reference cigarette smoke in the mechanism-based ToxTracker (by Imperial Brands and Reemtsma) # 2810/P427- In Vitro Assessment of Potential Chronic Toxicity of Smoke from Combustion of Flame Retarded Furnishings (by Science Strategies) # 3204/P851 - An intergrated in vitro mechanism of action assessment approach for evaluating E-cigarette flavoring compound toxicity (by Philip Morris International) # 3345/P158 - Comparing and combining in silico outcomes and in vitro mechanism-based assays to predict genotoxicity (By Lhasa) # 3510/P325 - The use of ROS scavengers and the ToxTracker assay for Mode-of-Action information as a follow-up for positive findings in the TK6 micronucleus assay (by Proctor & Gamble) You are welcome at our booth #  863

GTA annual meeting

Toxys will participate in the HESI GTTC 2020 Annual meeting and in the GTA annual meeting.